Transcript: Jefferson Capital Q1 2026 Earnings Conference Call

Jefferson Capital (JCAP) reported Q2 revenue of $177.5M, up 17.7% YoY, with collections growing 17.7% and deployments up 21.5%. Latin America saw the fastest growth. Operating expenses rose 45.6%, nearly three times revenue growth, driven by higher servicing and legal costs. Net income was $41.3M, or $0.67 per share, with adjusted figures higher. Debt remains a factor, with $226M drawn on its credit facility.

Jefferson Capital (JCAP) reported Q2 2026 earnings with total collections of $300.9M, up 18% YoY, and portfolio deployments of $152.2M, up 21% YoY. Adjusted EPS remained steady at $0.77, while total revenues rose 16.2% to $177.5M. The company highlighted record forward flow commitments and strong performance from Bluestem and Conn's portfolios. Management also announced entry into the Mexican debt market and added auto finance as a third asset class. Operating expenses increased 45.6% due to hig

Jefferson Capital, Inc. / DE (JCAP) filed an SEC Form 8-K — Results of Operations and Financial Condition. ​ Exhibit 99.1 ​ Jefferson Capital Reports Second Quarter 2026 Results ​ Collections Grow 18% to $300.9 Million and Deployments grow 21% to $152.2 Million Estimated Remaining Collections (“ERC”) up 18% to $3.4 Billion Pre-tax Income of $53.3 Million with Net Income of $41.3 Milli

Moderna and Merck's experimental melanoma vaccine, combined with Keytruda, reduced recurrence or death risk by 42% in a Phase 3 trial. Despite positive results, Moderna's shares fell 18%, likely due to high investor expectations. The vaccine is personalized using mRNA technology, targeting unique tumor mutations. Trial data showed 82.2% of patients treated with the vaccine and Keytruda were alive without recurrence after two years, compared to 70% with Keytruda alone.

Vertex Pharmaceuticals reported positive Phase III results for povetacicept, showing a 52% reduction in proteinuria in kidney disease patients. The drug's safety profile was similar to placebo. Vertex also discussed inaxaplin's potential in treating APOL1-mediated kidney disease, with Phase III AMPLITUDE trial results expected early next year. The company is engaging with payers for povetacicept's commercial coverage.

Novartis' remibrutinib showed 31.2% to 35.2% lower annualized relapse rates vs. teriflunomide in two late-stage MS trials. Both trials met primary endpoints. Novartis plans global regulatory filings. Analysts estimate potential peak sales over $4B, though not company guidance.